Early Intervention with PDE-5 Inhibitors Following Prostate Brachytherapy Improves Subsequent Erectile Function

Abstract

Prostate mono brachytherapy (PMB) is an accepted option for Gleason 6, low-volume Gleason 7 prostate cancers, and is being offered more frequently in younger patients. Unfortunately, erectile dysfunction can be a side effect from PMB, occurring frequently in the first 12 months following treatment. This study examines the use of early PDE-5 inhibitors (sildenafil citrate) in preventing subsequent erectile dysfunction following prostate brachytherapy.